At a Glance
- Company: Gilead Sciences; Genhouse Bio
- Location: Gilead (US); Genhouse (Suzhou, China)
- Deal value: $80M upfront; up to $1.45B milestones plus royalties (≈$1.5B+)
- Focus area: GH31, oral MAT2A inhibitor for MTAP‑deleted solid tumours (synthetic lethality)
- Next steps: Gilead to run global development; IND‑cleared in US and China and ready for clinical trials
What happened?
Gilead Sciences has signed a global licensing deal with China‑based Genhouse Bio for GH31, a clinic‑ready, oral MAT2A inhibitor that exploits synthetic lethality in MTAP‑deleted cancers. Under the agreement, Gilead will pay 80 million USD upfront and up to 1.45 billion USD in development, regulatory and commercial milestones, plus tiered, double‑digit royalties, bringing the total potential value to more than 1.5 billion USD.
Why does it matter?
GH31 adds a second synthetic lethality asset to Gilead’s oncology pipeline, following its earlier deal for a polymerase theta inhibitor, strengthening a strategy to target genetically defined tumour vulnerabilities. Synthetic lethal approaches, such as MAT2A inhibition in MTAP‑deleted tumours, aim to deliver highly selective treatments based on tumour genetics, potentially widening the precision oncology toolkit beyond PARP inhibitors.
Who’s behind it?
Gilead, which has been expanding in oncology through internal R&D, partnerships and acquisitions, framed the transaction as part of a disciplined effort to add best‑in‑class targeted therapies. Genhouse Bio, headquartered in Suzhou, has built a pipeline of synthetic lethality and epigenetic candidates, with GH31 as its lead asset alongside programmes targeting PRMT5, DHX9 and HDAC6.
How was it achieved?
Genhouse has already secured IND clearance for GH31 in both China and the United States, meaning the programme can move directly into first‑in‑human studies under Gilead’s leadership. The drug targets MAT2A in tumours with MTAP deletions, aiming to disrupt methionine and SAM metabolism and selectively impair cancer cells while sparing normal tissue, supported by preclinical synthetic lethality data in this axis.
What’s next?
Gilead will assume responsibility for global development and commercialisation of GH31, with plans to advance it into clinical trials in biomarker‑selected solid tumour populations. Observers expect Gilead to explore combinations with other targeted or immuno‑oncology agents as it builds a broader synthetic lethality franchise in oncology.